Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC25A34 and TMEM82 antisense RNA 1 (SLC25A34-AS1)
- Target
- SLC25A34-AS1
- Molecular classification
- Other, Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
SLC25A34 and TMEM82 antisense RNA 1 (SLC25A34-AS1) is a human long non-coding RNA (lncRNA) gene located on chromosome 1p36.21[4][6]. It is also known by the alias "RP11-169K16.4"[1][6][8][9]. As an lncRNA, SLC25A34-AS1 does not code for a protein but is thought to function in the post-transcriptional regulation of gene expression, potentially by acting as a competitive endogenous RNA (ceRNA) to modulate the activity of microRNAs and thereby influence other gene products[2].\n\nResearch has identified its differential expression in certain cancers—specifically, lower levels of a closely related lncRNA, RP11-169D4.1-001, are associated with a better prognosis in hypopharyngeal cancer patients[2]. While some lncRNAs are under investigation as potential drug targets or biomarkers, SLC25A34-AS1 currently lacks direct evidence for interacting drugs or established therapeutic applications. There are no known associated safety concerns, but further studies on its function and disease relevance are ongoing.
- Other names
- RP11-169K16.4
02
Biological functions
Post-transcriptional regulationGene expression regulationPotential tumor suppressor activity
03
Disease associations
Cancer (notably hypopharyngeal cancer, potential association with other tumors)
04
Biomarkers
RP11-169D4.1-001 (variant of this lncRNA) is a prognostic biomarker in hypopharyngeal squamous cell carcinoma[2]
Beyond the preview
Go deeper on SLC25A34 and TMEM82 antisense RNA 1 (SLC25A34-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC25A34 and TMEM82 antisense RNA 1 (SLC25A34-AS1).